Borrowing against a position you refuse to sell

When a holding is also an identity — a founder's stake, a legacy allocation — the cost of selling is rarely just tax. Pledge structures, margin thresholds and top-up mechanics decide whether a loan against securities is a tool or a trap.

A concentrated position carries two costs when it is sold: the tax event, and the loss of a compounding asset the owner believes in. For promoters and long-horizon families, the second cost is usually larger — which is why borrowing against the holding, rather than trimming it, is the default first question at our desk.

The variable that decides the outcome is not the interest rate. It is the margin-call trigger and how much notice accompanies it. Two facilities quoted within fifty basis points of each other can behave completely differently in a drawdown: one asks for a top-up within two working days of breaching a threshold, the other allows a cure period and accepts additional collateral rather than cash.

Loan-to-value bands vary by collateral quality. Listed large-cap equity and debt mutual funds attract the most generous advance rates; mid-cap and thinly traded stock attract far lower ones, and some lenders decline single-name concentration outright above a share of the portfolio. A facility structured across a basket rather than one line is usually cheaper and far more durable.

Practical checks before signing: what index or price level triggers a top-up, how many days the cure period runs, whether the lender can sell without instruction, whether partial prepayment releases pledged units proportionally, and whether the pledge is created in favour of the lender or a security trustee. Those five answers matter more than the headline rate.

Structured well, a loan against securities is the cheapest liquidity a large holder can access. Structured badly, it forces the exact sale it was meant to avoid, at the exact moment prices are worst.